Lead author: Jean-Francois Payen, jfpayen@ujf-grenoble.fr Three part clinical question: Patients: Adult patients admitted to the intensive care unit (ICU), initially requiring sedation with etomidate to facilitate rapid sequence endotracheal intubation (RSI). Intervention: 42-hour infusion of moderate-dose hydrocortisone or 0.9% sodium chloride, initiated six hours into admission following a baseline corticotrophin stimulation test. Primary outcome: Assessment of the vasopressor-dependence of patients with a cardiovascular Sequential Organ Failure Assessment (SOFA) score of 3 or 4 over the first 48 hours of admission. Secondary outcomes: Noradrenaline dose over the study period, maximum serum glucose, number of patients treated with insulin, maximum SOFA score and maximum cardiovascular SOFA score.
The study: Prospective double-blinded, randomised controlled trial conducted at the University Hospital of Grenoble between July 2008 and July 2010.
The study patients:
Inclusion criteria: Adult patients in the field or the emergency department requiring RSI, where a single dose of etomidate and suxamethonium was used. Exclusion criteria: Patients with septic shock requiring steroids, chronic adrenal insufficiency, pituitary disorder, HIV infection, concomitant or prior treatment with steroids, ketoconazole or fluconazole. Eligible: Of the 103 eligible patients, 99 were randomised. Four patients (two minors and two who refused consent) were excluded prior to randomisation.
Hydrocortisone group: (n=49, 48 analysed -one patient on extracorporeal life support was excluded). Thirty-eight patients received the full 42-hour infusion of 200 mg hydrocortisone diluted in 50 mL saline solution. One patient died and nine were discharged alive from ICU after 24 hours.
Control group: (n=50, 49 analysed -one patient excluded for receiving concomitant treatment with steroids). Forty patients received the full 42-hour infusion of 50 mL isotonic saline solution. Two patients died and seven were discharged alive from ICU after 24 hours.
The two groups were comparable with respect to age, sex
Corticosteroid after etomidate in critically ill patients
In this prospective, single-centre, slightly underpowered, double-blind randomised controlled trial (RCT) with intention-to-treat analysis, use of moderate-dose hydrocortisone in etomidate-related adrenal insufficiency was not shown to reduce the proportion of patients with a cardiovascular Sequential Organ Failure Assessment (SOFA) score of 3 or 4.
Level of evidence: 2B (CEBM, low quality RCT)
Appraised by: SK Dalay, S Jagannathan, S Chadwick and illness severity (Simplified Acute Physiology Score II and Injury Severity Score).
The evidence:
Corticotrophin stimulation test results were available for 90 patients. Etomidate-related adrenal insufficiency (defined as a change in serum cortisol concentration of <250 nmol/L and a serum 11β-deoxycortisol concentration >8 nmol/L) was present in 84% (38/45) and 91% (41/45) of patients in the control and hydrocortisone groups, respectively. For patients treated with noradrenaline at six hours, a significant decrease was observed in the required noradrenaline dose (p<0.01).
EBM questions:
1. Do the methods allow accurate testing of the hypothesis? Partly. The study was a two-year, prospectively conducted double-blinded RCT. However, it was single-centre and underpowered. By the authors' own admission, 50 patients per group were required to detect a reduction in cardiovascular SOFA score. A further limitation of the study was that the choice of etomidate for induction was at the discretion of the in-charge physician.
Do the statistical tests correctly test the results to allow differentiation of statistically significant results? Yes.
Statistical analysis was performed using Stata version 11.0 (Stata Corp, College Station, TX), p-values ≤0.05 were declared statistically significant. Chi-square tests were used for categorical variables, and non-parametric Mann-Whitney tests were used for continuous variables. A random effect linear model was used to assess statistical significance of temporal changes. Bonferroni' s correction was used where multiple comparisons were made of interactions between groups and time (p≤0.10). 3. Are the conclusions valid in light of the results? Yes. Use of moderate-dose hydrocortisone in etomidate-related adrenal insufficiency was not shown to reduce the proportion of patients with a cardiovascular SOFA score of 3 or 4, nor was any statistical significance shown between use of hydrocortisone and the secondary and other outcomes of the study. However, the use of hydrocortisone was associated with a statistically significant decrease in noradrenaline dose required between 24 and 48 hours of ICU admission, but whether the difference is clinically significant was not discussed. 4. Did results get omitted and why? Yes. Four patients (two minors and two who refused consent) were omitted prior to randomisation and were not therefore analysed. One patient receiving extracorporeal life support was omitted and not analysed. One patient was also omitted and not analysed from the control group for receiving concomitant treatment with steroids.
Did they suggest areas for further research? Yes.
Hydrocortisone supplementation was initiated six hours after induction in this study to allow time for random cortisol levels and corticotrophin stimulation tests. The authors suggest further research into the effects of hydrocortisone supplementation given together with etomidate at induction. However, the authors did not investigate any harm, such as an increased incidence of infection, which may have been caused secondary to the administration of hydrocortisone. Obtaining ethical approval and funding for a larger study may be difficult since lack of harm has not been demonstrated in this pilot. 6. Did they suggest any recommendations based on the results and were they appropriate? No. Specific recommendations were not made. 7. Is the study relevant to my clinical practice? Yes. Etomidate is well known to cause adrenal suppression. But it is still commonly used for RSI in haemodynamically unstable, critically unwell patients. Hence, knowledge of any agent which could improve its adverse endocrine profile would be beneficial. The study did not include patients with septic shock. Therefore, the results cannot be generalised across all clinical scenarios where an emergency RSI may be required. 8. What level of evidence does this study represent? 2B: Doubleblind, randomised controlled, intention-to-treat trial with a risk of bias, (underpowered). 9. What grade of recommendation can I make on this result alone? C (CEBM). 10. What grade of recommendation can I make when this study is considered along with other available evidence? C. 11. Should I change my practice because of these results? No.
Though the study is a double-blind randomised, controlled trial, it is underpowered and single-centred, without any specific recommendations. 12. Should I audit my results? No. With current evidence, hydrocortisone cannot be used to treat anticipated adrenal suppression and hence the cardiovascular adverse effects caused by etomidate.
